ImmunityBio Shares 11% Higher on License Application Resubmission for N-803
By Dean Seal
Shares of ImmunityBio rose after the company resubmitted a biological license application for its investigational bladder cancer treatment N-803.
The stock was up 11% at $1.44 in early trading. Shares have fallen 71% year-to-date.
The clinical-stage immunotherapy company said Monday that it resubmitted the application to the U.S. Food and Drug Administration.
The application is supported by the results of ImmunityBio's studies in bladder cancer, including a study published last November.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
October 23, 2023 10:45 ET (14:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now